NOGA Therapeutics
NOGA Therapeutics is a pioneering gene therapy company that leverages lentiviral vector technology to develop targeted, transformative therapies for severe and chronic illnesses. Their mission is to create life-changing gene therapies that provide durable, precise, and safe solutions, aiming to eliminate suffering for patients with rare and severe diseases worldwide. Building on a validated platform of gene delivery technology, they focus on engineering hematopoietic stem cells to deliver biological therapies, including solutions for diseases like X-linked Agammaglobulinemia (XLA) and Parkinson’s disease.
Industries
Nr. of Employees
small (1-50)
NOGA Therapeutics
3 Pinhas Sapir St, Ness Ziona, 7403626, Weizmann science park, Israel
Patents
Lentiviral vectors for therapeutic expression of BTK in haematopoietic cells
US-11464872-B2
View Details
Lentiviral vectors for therapeutic expression of BTK in haematopoietic cells
US-11464872-B2
View DetailsProducts
Lentiviral HSC gene therapy candidate for BTK deficiency (X-linked agammaglobulinemia)
A lentiviral HSC-based gene therapy candidate designed to deliver a functional BTK sequence to patient-derived stem cells to restore B-cell development and antibody production after a single treatment; includes preclinical proof-of-concept in mouse models and a granted US patent covering the approach.
HSC-derived macrophage therapeutic program for Parkinson's disease (preclinical)
Preclinical program exploring HSC-derived macrophage engineering to enable sustained, localized delivery of therapeutic molecules to the brain as a potential disease-modifying approach for Parkinson's disease.
Lentiviral HSC gene therapy candidate for BTK deficiency (X-linked agammaglobulinemia)
A lentiviral HSC-based gene therapy candidate designed to deliver a functional BTK sequence to patient-derived stem cells to restore B-cell development and antibody production after a single treatment; includes preclinical proof-of-concept in mouse models and a granted US patent covering the approach.
HSC-derived macrophage therapeutic program for Parkinson's disease (preclinical)
Preclinical program exploring HSC-derived macrophage engineering to enable sustained, localized delivery of therapeutic molecules to the brain as a potential disease-modifying approach for Parkinson's disease.
Services
Access to an automated closed-system cell and gene therapy manufacturing platform through a manufacturing partner to produce patient-specific HSC-based therapies with improved robustness and reproducibility.
Access to an automated closed-system cell and gene therapy manufacturing platform through a manufacturing partner to produce patient-specific HSC-based therapies with improved robustness and reproducibility.
Expertise Areas
- Lentiviral vector-based gene therapy
- Hematopoietic stem cell (HSC) reprogramming
- Macrophage-based therapeutic delivery
- Cell and gene therapy manufacturing
Key Technologies
- Lentiviral vector gene delivery
- Hematopoietic stem cell transduction and reprogramming
- Engineered tissue-resident macrophages
- Automated closed-system cell and gene therapy manufacturing platforms